featured
Safety of Next-Generation Oral SERD Camizestrant as Monotherapy in ER+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Phase 1 dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results
Ann. Oncol 2024 May 08;[EPub Ahead of Print], E Hamilton, M Oliveira, N Turner, J García-Corbacho, C Hernando, EM Ciruelos, P Kabos, MR Borrego, A Armstrong, MR Patel, C Vaklavas, C Twelves, V Boni, J Incorvati, T Brier, L Gibbons, T Klinowska, JPO Lindemann, CJ Morrow, A Sykes, R BairdFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.